scholarly journals In-utero aspiration vs expectant management of anechoic fetal ovarian cysts: open randomized controlled trial

2018 ◽  
Vol 52 (2) ◽  
pp. 159-164 ◽  
Author(s):  
C. Diguisto ◽  
N. Winer ◽  
G. Benoist ◽  
H. Laurichesse-Delmas ◽  
J. Potin ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Expectant Management ◽  
In Utero ◽  
Ovarian Cysts ◽  
Randomized Controlled

scholarly journals Cervical Pessary versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women with Placenta Previa: A Randomized Controlled Trial

2019 ◽  
Vol 09 (02) ◽  
pp. e160-e166
Author(s):  
Irene Stafford ◽  
Thomas Garite ◽  
Kimberly Maurel ◽  
C. Combs ◽  
Kent Heyborne ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Primary Outcome ◽  
Placenta Previa ◽  
Controlled Trial ◽  
Expectant Management ◽  
Randomized Controlled ◽  
Cervical Pessary ◽  
Multicenter Randomized Controlled Trial ◽  
To Receive ◽  
Type Of Delivery

Objective This multicenter randomized controlled trial compared cervical pessary (CP) versus expectant management (EM) in women with placenta previa between 22.0 and 32.0 in prolonging gestation until ≥ 36.0 weeks' gestation. Study Design This study took place from November 2016 to June 2018. Women were randomized to receive either the Bioteque CP or EM. The pessary was removed at ≥ 36.0 weeks unless indicated. The primary outcome was gestational age (GA) at delivery, with secondary outcomes including need for transfusion, number and duration of antepartum admissions, type of delivery, and neonatal outcomes. A total of 140 patients were needed to show a 3-week prolongation of pregnancy in the pessary group; however, the trial was stopped early due to budgetary issues. Results Of the 33 eligible women, 17 were enrolled. Although not statistically significant, the mean GA at delivery in the CP group was greater than women in the EM group (36.5 ± 1.23 vs. 36.0 ± 2.0; p = 0.1673). The number and duration of antepartum admissions was greater in the EM group (2.7 ± 0.58 vs. 16.0 ± 22.76 days; p = 0.1264) as well. Conclusion Although the study was underpowered to determine the primary outcome, safety and feasibility of CP in pregnancies complicated with previa were demonstrated.

scholarly journals A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Madeline M. Ross ◽  
Sara Cherkerzian ◽  
Nicole D. Mikulis ◽  
Daria Turner ◽  
Julian Robinson ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Brain Injury ◽  
White Matter ◽  
Controlled Trial ◽  
In Utero ◽  
Pomegranate Juice ◽  
Significant Group ◽  
Randomized Controlled ◽  
White Matter Microstructure ◽  
The Impact

AbstractAnimal studies have demonstrated the therapeutic potential of polyphenol-rich pomegranate juice. We recently reported altered white matter microstructure and functional connectivity in the infant brain following in utero pomegranate juice exposure in pregnancies with intrauterine growth restriction (IUGR). This double-blind exploratory randomized controlled trial further investigates the impact of maternal pomegranate juice intake on brain structure and injury in a second cohort of IUGR pregnancies diagnosed at 24–34 weeks’ gestation. Ninety-nine mothers and their eligible fetuses (n = 103) were recruited from Brigham and Women’s Hospital and randomly assigned to 8 oz pomegranate (n = 56) or placebo (n = 47) juice to be consumed daily from enrollment to delivery. A subset of participants underwent fetal echocardiogram after 2 weeks on juice with no evidence of ductal constriction. 57 infants (n = 26 pomegranate, n = 31 placebo) underwent term-equivalent MRI for assessment of brain injury, volumes and white matter diffusion. No significant group differences were found in brain volumes or white matter microstructure; however, infants whose mothers consumed pomegranate juice demonstrated lower risk for brain injury, including any white or cortical grey matter injury compared to placebo. These preliminary findings suggest pomegranate juice may be a safe in utero neuroprotectant in pregnancies with known IUGR warranting continued investigation.Clinical trial registration: NCT04394910, https://clinicaltrials.gov/ct2/show/NCT04394910, Registered May 20, 2020, initial participant enrollment January 16, 2016.

Sign in / Sign up

Export Citation Format

Share Document